Roche and Affymetrix get US nod for first-of-its-kind DNA test
This article was originally published in Clinica
Executive Summary
The US FDA has cleared, for the first time, a DNA microarray test that could help doctors determine the success of medications for a variety of conditions, including cardiac disease, psychiatric disease and cancer. The AmpliChip Cytochrome P450 genotyping test, made by Roche Molecular Systems, of Pleasanton, California was cleared for use with Affymetrix' GeneChip Microarray system. According to the agency, the product could pave the way for the development of similar tests.